Lung Cancer, An Issue of Surgical Oncology Clinics

Mark J. Krasna

Description

In this issue of Surgical Oncology Clinics of North America, Guest Editor Mark Krasna and colleagues discuss a wide range of topics devoted to lung cancer. Articles focus on pathology; updated staging systems; epidemiology of lung cancer - smoking, second hand smoke, and genetics; molecular markers for incidence, prognosis, and response to therapy; screening; diagnostic work-up; non-invasive staging techniques; surgical resection; the role of surgery following induction therapy for stage III NSCLC; the role of adjuvant chemotherapy in NSCLC (stages I-III); and much more.

Sujets

• Médecine
• Médecine Générale
• Oncology
• Medical

Informations

• Publié par: Saunders
• Date de parution: 28 octobre 2011
• Nombre de lectures: 0
• EAN13: 9781455712168
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Surgical Oncology Clinics of North America , Vol. 20, No. 4, October 2011
ISSN: 1055-3207
doi: 10.1016/S1055-3207(11)00055-X

Contributors
Surgical Oncology Clinics of North America
Lung Cancer
GUEST EDITOR: Mark J. Krasna, MD
Meridian Health System, Neptune, NJ, USA
CONSULTING EDITOR: Nicholas J. Petrelli, MD
ISSN  1055-3207
Volume 20 • Number 4 • October 2011

Contents
Cover
Contributors
Forthcoming Issues
Foreword
Lung Cancer
Epidemiology of Lung Cancer: Smoking, Secondhand Smoke, and Genetics
Screening for Lung Cancer: Challenges for the Thoracic Surgeon
The Changing Pathology of Lung Cancer
Updated Staging System for Lung Cancer
Diagnostic Workup of Lung Cancer
A Review of Noninvasive Staging of the Mediastinum for Non–Small Cell Lung Carcinoma
Surgical Staging for Non–Small Cell Lung Cancer
The Surgical Management of Stage I and Stage II Lung Cancer
Role of Surgery Following Induction Therapy for Stage III Non–Small Cell Lung Cancer
Extensive Resections: Pancoast Tumors, Chest Wall Resections, En Bloc Vascular Resections
Role of Adjuvant Chemotherapy in NSCLC (Stages I to III)
Role of Surgery in Small Cell Lung Cancer
Surgical and Endoscopic Palliation of Advanced Lung Cancer
Index
Surgical Oncology Clinics of North America , Vol. 20, No. 4, October 2011
ISSN: 1055-3207
doi: 10.1016/S1055-3207(11)00057-3

Forthcoming Issues
Surgical Oncology Clinics of North America , Vol. 20, No. 4, October 2011
ISSN: 1055-3207
doi: 10.1016/j.soc.2011.08.002

Foreword

Nicholas J. Petrelli, MD ,
Helen F. Graham Cancer Center, 4701 Ogletown-Stanton Road, Suite 1213, Newark, DE 19713, USA
E-mail address: [e-mail]


Nicholas J. Petrelli, MD, Consulting Editor
This issue of the Surgical Oncology Clinics of North America is devoted to lung cancer. The guest editor is Mark J. Krasna, MD. Dr Krasna has been the Medical Director of The Cancer Institute at St Joseph’s Towson and Physician Advisor, Cancer Care for the Catholic Health Initiatives. Previously, he had been Director of the General Thoracic Surgery Department at the University of Maryland School of Medicine and Chief of Thoracic and Cardiovascular Surgery at the Baltimore Veteran’s Administration Medical Center. Dr Krasna’s career has spanned the gamut of the treatment and prevention of lung cancer. His career has centered around clinical trials and the multidisciplinary care team approach of the cancer patient. As principal investigator of the National Cancer Institute Community Cancer Centers program at St Joseph’s Towson Cancer Institute, he led the project, evaluating outcomes from the multidisciplinary team approach to patients with lung and colorectal cancer. This will be the first prospective outcomes evaluation of multidisciplinary cancer care to be reported in the literature.
Dr Krasna has assembled a group of talented individuals for this edition of the Surgical Oncology Clinics of North America . This edition discusses pathology, the updated staging system, epidemiology, molecular markers, and surgical palliation among other topics for lung cancer. The gamut of such discussion is illustrated by the article by Cheng and Wood entitled, “Surgical and Endoscopic Palliation of Advanced Lung Cancer.” This article gives detailed descriptions of the treatment for airway obstruction, malignant pleural effusions, and hemoptysis.
Although lung cancer is a preventable cancer, it still is responsible for the majority of cancer deaths in the United States. Prevention is the key, but once the lung cancer has been established, patients need talented individuals like those in this issue of the Surgical Oncology Clinics of North America to make sure they get high-quality multidisciplinary care.
I thank Dr Mark Krasna and his colleagues for this outstanding issue of the Clinics and encourage the readers to share this information with all of their trainees and colleagues.
Respectfully,
Surgical Oncology Clinics of North America , Vol. 20, No. 4, October 2011
ISSN: 1055-3207
doi: 10.1016/j.soc.2011.08.004

Preface
Lung Cancer

Mark J. Krasna, MD ,
Meridian Health System, Neptune, NJ, USA
E-mail address: [e-mail]


Mark J. Krasna, MD, Guest Editor
This issue of the Surgical Oncology Clinics of North America is dedicated to a thorough review of lung cancer. This disease, often referred to as “the forgotten cancer” (hence the “clear” survivor ribbon), is actually one of the most important of malignancies, causing major illness affecting over 1.5 million patients worldwide, and most importantly, killing more men and women than the next three cancers combined. With such a high impact on the health and financial burden to North American and worldwide patients, one could reasonably have expected improvements over the years, such as we have seen in breast and prostate cancer. Unfortunately, the advances made in screening for those diseases, as well as use of hormone treatment and molecular targeted therapies, have led to successes unrivaled as yet in lung cancer.
This Surgical Oncology Clinics of North America issue, however, is timely, coming after the newest revision in the staging of lung cancer, new diagnostic and screening modalities and pathologic definitions, and, of course, progress in surgical management strategies. Given the “shrinking global distances,” we have assembled a panel of experts from around the world, who bring local, regional, and global perspective on their subject matter.
Drs Fan and Schraeder provide a thorough, yet concise overview of the newest pathologic definitions using the WHO criteria for non-small cell lung cancer (NSCLC), with an emphasis on the importance of immunostaining on clinical decision-making.
Dr Dresler and coworkers introduce the epidemiology of the incidence and prevalence of NSCLC and relate it to the smoking burden and its impact on society in North America and across the globe.
Dr Altorki and colleagues update the recent series of screening trials, which have finally shown unequivocally the value of screening computed tomography in high-risk patients for lung cancer. Drs Sugarbaker and colleagues provide a thoughtful and complete algorithm to the workup of the patient with lung cancer, from both the diagnostic and the physiologic perspective. I would also encourage readers to review the recently released “Ontario Guidelines on NSCLC.”
Dr Goldstraw, who led the revision of the Union Internationale Contra Canceur (International union against cancer) and American Joint Committee on Cancer systems under the auspices of the International Society for the Study of Lung Cancer, gives a superb overview of the new staging system, highlighting the changes and the clinical implications.
Dr Bauer and coworkers discuss the recent progress made in the “noninvasive” and “minimally invasive” approaches to staging and diagnosis of lung cancer. This is followed by Dr Gamliel’s thorough description of the use of surgical staging and restaging of NSCLC, following in the tradition of Pearson and Ginsberg.
Dr Sonett and coworkers describe the approaches to early stage lung cancer with an emphasis on the use of video-assisted thoracoscopic surgery and newer robotic techniques. Drs Rendina and colleagues dive into their vast experience with major extensive en bloc and sleeve resections for locally advanced NSCLC. Dr Daly and colleagues have pooled their experiences that have defined the successful use of multimodality in the treatment of stage 3 NSCLC, changing the face of this disease and making the word “cure” a real option for these patients.
Dr Wood discusses the important issue of palliation for patients who are not curative candidates, but in whom some improvement in quality of life is possible. Dr Bueno rounds out the discussion on NSCLC with an emphasis on the newest data for the value of adjuvant therapy using chemo and/or molecular targeted therapy for all but the very earliest stages (Ia) of this dreaded disease.
Finally, Dr Yang and coworkers describe the intriguing new approach to utilizing surgery as one of the modalities for treating patients with small-cell lung cancer.
I hope you enjoy this volume and benefit from the expert opinions and experiences included. I wish to thank Dr Nick Petrelli, my good friend and mentor, for giving me this opportunity to edit this issue of the Surgical Oncology Clinics .
Surgical Oncology Clinics of North America , Vol. 20, No. 4, October 2011
ISSN: 1055-3207
doi: 10.1016/j.soc.2011.07.003

Epidemiology of Lung Cancer: Smoking, Secondhand Smoke, and Genetics

Matthew A. Steliga, MD a , * , Carolyn M. Dresler, MD, MPA b
a Division of Cardiothoracic Surgery, University of Arkansas for Medical Sciences, 4301 West Markham Street #713, Little Rock, AR 72205, USA
b Tobacco Prevention and Cessation Program, State of Arkansas Department of Health, 4815 West Markham Street #3, Little Rock, AR 72205-3867, USA
* Corresponding author.
E-mail address: [e-mail]

Abstract
The link between smoking and development of lung cancer has been demonstrated, not only for smokers but also for those exposed to secondhand smoke. Despite the obvious carcinogenic effects of tobacco smoking, not all smokers develop lung cancer, and conversely some nonsmokers can develop lung cancer in the absence of other environmental risk factors. A multitude of genetic factors are beginning to be explored that inter